JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

Kodu・Aktsiate loetelu・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Avatud

SektorTervishoid

29.91 9.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.4

Max

32.56

Põhinäitajad
By Trading Economics
Sissetulek	-85K 53M
Müük	4.2M 153M
P/E Sektori keskmine	15.518 60.328
Aktsiakasum	0.68
Kasumimarginaal	34.53
Töötajad	182
EBITDA	612K 81M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+26.05% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	241M 3.2B
Eelmine avamishind	20.75
Eelmine sulgemishind	29.91

Uudiste sentiment

By Acuity

28%

72%

62 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

N/A / 24.28 Toetus ja vastupanu

Catalyst Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26. apr 2026, 21:14 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Major Central Bank -2-

24. apr 2026, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Intertek Group Rejects EQT's Revised Offer

26. apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26. apr 2026, 23:44 UTC

Tulu

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26. apr 2026, 23:44 UTC

Tulu

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls Amid Dollar's Strength -- Market Talk

26. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26. apr 2026, 05:12 UTC

Tulu

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26. apr 2026, 05:12 UTC

Tulu

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26. apr 2026, 05:12 UTC

Tulu

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26. apr 2026, 05:12 UTC

Tulu

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24. apr 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Scoring the Cook Era -- Barrons.com

24. apr 2026, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

24. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 20:09 UTC

Tulu

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. apr 2026, 19:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. apr 2026, 19:25 UTC

Omandamised, ülevõtmised, äriostud

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. apr 2026, 19:22 UTC

Tulu

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. apr 2026, 19:06 UTC

Tulu

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. apr 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. apr 2026, 18:30 UTC

Omandamised, ülevõtmised, äriostud

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. apr 2026, 18:28 UTC

Omandamised, ülevõtmised, äriostud

Intertek Rejects Revised EQT Offer

24. apr 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. apr 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. apr 2026, 17:42 UTC

Tulu

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. apr 2026, 17:28 UTC

Tulu

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Catalyst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

26.05% tõus

12 kuu keskmine prognoos

Keskmine 34.5 USD 26.05%

Kõrge 35 USD

Madal 33 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Catalyst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Catalyst Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 24.28Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

62 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.